English  |  正體中文  |  简体中文  |  Total items :2809329  
Visitors :  26856584    Online Users :  214
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"mok t"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-25 of 51  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-06-27T07:07:44Z Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors Lin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; Lin Z.-Z.; CHONG-JEN YU; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T.
臺大學術典藏 2022-06-27T07:02:01Z Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T.
臺大學術典藏 2022-06-27T07:01:52Z A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: Results of the phase II randomized ABIGAIL study (BO21015) Mok T.; Gorbunova V.; Juhasz E.; Szima B.; Burdaeva O.; Orlov S.; CHONG-JEN YU; Archer V.; Hilton M.; Delmar P.; Pallaud C.; Reck M.
臺大學術典藏 2022-06-27T07:01:46Z Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer Pallaud C.; Reck M.; Juhasz E.; Szima B.; CHONG-JEN YU; Burdaeva O.; Orlov S.; Hilton M.; Archer V.; Mok T.
臺大學術典藏 2022-06-27T07:01:34Z Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L.
臺大學術典藏 2022-06-27T07:00:23Z First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study Park K.; CHONG-JEN YU; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T.
臺大學術典藏 2022-06-27T07:00:18Z Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L.
臺大學術典藏 2022-06-27T06:59:45Z Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T.
臺大學術典藏 2022-06-10T06:11:12Z Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors Lin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; ZHONG-ZHE LIN; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T.
臺大學術典藏 2022-05-10T08:10:07Z Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H.
臺大學術典藏 2022-02-21T02:04:31Z APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy Lau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M.
臺大學術典藏 2021-08-11T03:46:50Z Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors Lin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; ZHONG-ZHE LIN; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T.
臺大學術典藏 2020-12-02T02:33:14Z Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer Blackhall F.; Ross Camidge D.; Shaw A.T.; Soria J.-C.; Solomon B.J.; Mok T.; Hirsh V.; J?Nne P.A.; Shi Y.; Pan-Chyr Yang; De Pas T.; Hida T.; De Castro Carpe?O J.; Lanzalone S.; Polli A.; Iyer S.; Reisman A.; Wilner K.D.; Kim D.-W.; Blackhall F.; PAN-CHYR YANG et al.
臺大學術典藏 2020-08-13T06:33:58Z Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors Mok T.; Yang C.-H.; Leung L.; Lam K.C.; Lin C.-C.; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH; Lin Z.-Z.; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lin C.-C.;Hsu H.-H.;Sun C.-T.;Jin-Yuan Shih;Lin Z.-Z.;Yu C.-J.;Chen G.G.;Hsin M.K.Y.;Lam K.C.;Leung L.;Yang C.-H.;Mok T.
臺大學術典藏 2020-08-12T06:34:46Z Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy Mok T.;Wu Y.-L.;Lee J.S.;Chong-Jen Yu;Sriuranpong V.;Sandoval-Tan J.;Ladrera G.;Thongprasert S.;Srimuninnimit V.;Liao M.;Zhu Y.;Zhou C.;Fuerte F.;Margono B.;Wen W.;Tsai J.;Truman M.;Klughammer B.;Shames D.S.;Wu L.; Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L.
臺大學術典藏 2020-05-26T09:27:18Z Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors Lin C.-C;Hsu H.-H;Sun C.-T;Shih J.-Y;Lin Z.-Z;Yu C.-J;Chen G.G;Hsin M.K.Y;Lam K.C;Leung L;Chih-Hsin Yang;Mok T.; Lin C.-C; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; CHIH-HSIN YANG; Mok T.
臺大學術典藏 2020-05-26T09:27:11Z INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer Wu Y.-L;Park K;Soo R.A;Sun Y;Tyroller K;Wages D;Ely G;Chih-Hsin Yang;Mok T.; Wu Y.-L; Park K; Soo R.A; Sun Y; Tyroller K; Wages D; Ely G; CHIH-HSIN YANG; Mok T.
臺大學術典藏 2020-05-26T09:27:01Z Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M.
臺大學術典藏 2020-05-26T09:26:59Z First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.
臺大學術典藏 2020-05-26T09:26:58Z Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis Popat S;Mok T;Chih-Hsin Yang;Wu Y.-L;Lungershausen J;Stammberger U;Griebsch I;Fonseca T;Paz-Ares L.; Popat S; Mok T; CHIH-HSIN YANG; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L.
臺大學術典藏 2020-05-26T09:26:54Z Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V.
臺大學術典藏 2020-05-26T09:26:51Z Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N
臺大學術典藏 2020-05-26T09:26:48Z Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K.
臺大學術典藏 2020-05-26T09:26:48Z First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:47Z 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG

Showing items 1-25 of 51  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page